Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer-Reference-Cited by-同舟云学术

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer

Published:2021-09-16 Issue:2 Volume:150 Page:308-316
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Krens Stefanie D.¹^ORCID,Boxtel Wim²^ORCID,Uijen Maike J. M.²,Jansman Frank G. A.³⁴,Desar Ingrid M. E.²,Mulder Sasja F.²,Herpen Carla M. L.²,Erp Nielka P.¹

Affiliation:

1. Department of Pharmacy Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen The Netherlands

2. Department of Medical Oncology Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen The Netherlands

3. Department of Clinical Pharmacy Deventer Hospital Deventer The Netherlands

4. Unit of Pharmacotherapy, Pharmacoepidemiology and Pharmacoeconomics Groningen Research Institute of Pharmacy, University of Groningen Groningen The Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33797

Reference46 articles.

1. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

2. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

3. FDA.Cabometyx prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692s008lbl.pdf. Accessed December 1 2020.

4. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

5. Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma;Clinical Genitourinary Cancer;2024-06

2. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care;British Journal of Cancer;2024-01-25

3. Results of the first international quality control programme for oral targeted oncolytics;British Journal of Clinical Pharmacology;2023-10-13

4. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087);Clinical Cancer Research;2023-07-31

5. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer;Cancers;2023-01-03